Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

0 million in the prior year.

Net loss per share applicable to common stockholders during the fourth quarter of 2007 was ($0.19), compared to a net loss per share of ($0.22) in the prior quarter, and a net loss per share of ($0.44) in the comparable quarter of last year. Net loss per share applicable to common stockholders during the full year of 2007 was ($0.96), down from a net loss per share of ($1.38) in the full year of 2006.

"Having received FDA approval for MOXATAG and raising more than $20 million in the first quarter of 2008, we believe we are now in a very favorable position to be considering strategic alternatives for the Company," stated Edward M. Rudnic, Ph.D., president and CEO of MiddleBrook. "We intend to work closely with Morgan Stanley over the coming months to drive the strategic process toward a potential transaction having the greatest benefit for our shareholders."

OPERATIONAL HIGHLIGHTS

Keflex(R) Capsules (Cephalexin, USP) - Commercialization Update

During the fourth quarter, MiddleBrook continued the commercialization of its 750 mg strength Keflex capsules through a targeted and dedicated national contract sales force. Based on prescription data from IMS Health, total prescriptions filled for Keflex 750 mg capsules in the fourth quarter of 2007 were 79,628 prescriptions, compared to third quarter 2007 prescriptions of 83,767.

MiddleBrook is currently marketing Keflex 750 mg capsules through its sales force of approximately 30 contract sales representatives and three MiddleBrook district sales managers.

MOXATAG(TM) (amoxicillin extended-release) Tablets Approval - January 23, 2008

On January 23, 2008, MiddleBrook received U.S. Food and Drug Administration (FDA) approval of the Company's New Drug Application (NDA) for its once-daily amoxicillin PULSYS(R) product, under the trade name, MOXATAG(TM) (amoxicillin extended-release) Tablets. MOXATAG is approved for the treatment of pharyngitis an
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 According to ... Slide Imaging), Analytics (Image Analysis Software), Delivery Modes (Web ... Forecasts & Trends to 2018", published by MarketsandMarkets, analyzes ... geographies such as North America , ... , and the Rest of the World (RoW). ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today a ... to provide access to Nanosyn,s microfluidics screening and ... for novel small molecule therapeutics. ... work with FORMA Therapeutics to explore key pathways ... FORMA Therapeutics, decision to work with us is ...
(Date:7/29/2014)... Colo. , July 29, 2014  Cannabis ... in cannabis formulation-based drug development and related consulting, ... Times for taking a strong position in opposition ... Sunday, July 27, 2014 publication.  The New York ... and articles this week exploring the issue called ...
(Date:7/29/2014)... Denver, CO (PRWEB) July 29, 2014 ... and soiled linen collection and transport solutions for hospitals, ... Society for Healthcare Engineering (ASHE) Annual Conference & Technical ... TransVac will present its technology for making hospitals cleaner, ... operational costs over the hospital’s life cycle. Staff ...
Breaking Biology Technology:Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
... Cardium Therapeutics (Amex:,CXM) today announced that its annual ... at 9:00 a.m. Pacific Time, at the San Diego ... The record date for,stockholders entitled to vote at the ... http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ), About Cardium, Cardium Therapeutics, Inc. ...
... and PHILADELPHIA, Pennsylvania, May 23, Shire Limited ("Shire") (LSE: ... an,application has been made to the UK Listing Authority ... of 5 pence each in the,capital of Shire to ... on the,London Stock Exchange. Dealings will commence today at ...
... Surveillance System Detects ... Emerging Pattern, ... hours,on a recent Friday, 20 people arrived, one by one, for ... various,gastrointestinal symptoms, including nausea and diarrhea., A coincidence? Or the ...
Cached Biology Technology:Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008 2Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008 3Application for Listing of Shire Limited Ordinary Shares 2Application for Listing of Shire Limited Ordinary Shares 3E. coli Outbreak in New Jersey? 2E. coli Outbreak in New Jersey? 3
(Date:7/28/2014)... Fifteen years ago, MIT professor John Essigmann and colleagues from ... HIV drug. They thought if they could induce the virus ... eventually die out a strategy that our immune system ... a drug, which caused HIV to mutate at an enhanced ... from patients in a small clinical trial reported in 2011. ...
(Date:7/28/2014)... Solanum pennellii , a wild relative of the domestic ... researchers including the labs headed by Professors Neelima Sinha ... Plant Biology. The new genome information may help breeders ... July 27 in the journal Nature Genetics , ... University in Germany. The UC Davis labs carried out ...
(Date:7/28/2014)... of a new study suggest two ways to effectively address ... well in obese women, compared to women of a normal ... method, researchers say, but as the population has increased in ... for obese women. Studies have consistently found that obesity has ... may in turn affect how well the pill prevents pregnancy. ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4Strategies identified to improve oral contraceptive success with obese women 2
... their hunting sequence - capture, handling and consumption - to ... ones they are better off leaving alone or dropping mid-way ... then they assess its size, and finally they taste it. ... the Smithsonian Tropical Research Institute in Panama is published online ...
... A new multi-university study reports that differences in bacterial colonization ... to changes in the expression of genes involved in the ... 30 issue of BioMed Central,s open access journal Genome ... joint effort of University of Illinois, Texas A&M University, Miami ...
... mesenchymal stem cells that promotes growth appears to spur ... of multiple sclerosis (MS), researchers at Case Western Reserve ... is embargoed until published in the online version of ... Standard Time on Sunday, May 20. In animals ...
Cached Biology News:What sounds good doesn't always taste good 2Breast-fed babies' gut microbes contribute to healthy immune systems 2Growth factor in stem cells may spur recovery from MS 2
EML1 (K-16)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
... ,• Eliminates nonspecific products due to ... specificity allows extension through DNA regions which ... Leaves an 'A' overhang ,TEMPase II ... DNA Polymerase that remains inactive at ...
Biology Products: